Movement Alert｜EVEREST MED Rises 5.72% in Regular Trading, Medical Industry Policy and mRNA Pipeline Progress Boost Sentiment

Market Focus09-30 09:52

On September 30, EVEREST MED (01952.HK) rose 5.72% in regular trading, trading at HKD 29.62/share, with turnover of HKD 60.70 million.

On the news front, ten government departments jointly released the Medical Industry Development Plan, which calls for deepening AI-enabled upgrades across the pharmaceutical value chain, supporting AI and supercomputing applications in target discovery, molecular design, clinical trials, and production management. EVEREST MED, which operates a proprietary mRNA technology platform, plans to initiate an IITIb study of its mRNA tumor vaccine EVM16 in the fourth quarter. The broader biotechnology sector showed strength, with CANSINOBIO surging 17.23%.

Additionally, the company recently announced the establishment of an ESG committee effective September 28, with four members appointed including Chairman Wu Yifang, further enhancing its corporate governance structure. The company also issued approximately 385,000 shares under its share incentive plan on September 28. Earlier in September, EVEREST MED secured NMPA approval for Xingbituo (etripamil nasal spray) for the treatment of adult PSVT, marking its first approved cardiovascular product in China.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1189388761?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-30 09:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189388761","market":"hk","top_or_hot":-1,"title":"Movement Alert｜EVEREST MED Rises 5.72% in Regular Trading, Medical Industry Policy and mRNA Pipeline Progress Boost Sentiment","media":"Market Focus","content":"<p><p>On September 30, EVEREST MED (01952.HK) rose 5.72% in regular trading, trading at HKD 29.62/share, with turnover of HKD 60.70 million.</p><p>On the news front, ten government departments jointly released the Medical Industry Development Plan, which calls for deepening AI-enabled upgrades across the pharmaceutical value chain, supporting AI and supercomputing applications in target discovery, molecular design, clinical trials, and production management. EVEREST MED, which operates a proprietary mRNA technology platform, plans to initiate an IITIb study of its mRNA tumor vaccine EVM16 in the fourth quarter. The broader biotechnology sector showed strength, with CANSINOBIO surging 17.23%.</p><p>Additionally, the company recently announced the establishment of an ESG committee effective September 28, with four members appointed including Chairman Wu Yifang, further enhancing its corporate governance structure. The company also issued approximately 385,000 shares under its share incentive plan on September 28. Earlier in September, EVEREST MED secured NMPA approval for Xingbituo (etripamil nasal spray) for the treatment of adult PSVT, marking its first approved cardiovascular product in China.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜EVEREST MED Rises 5.72% in Regular Trading, Medical Industry Policy and mRNA Pipeline Progress Boost Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜EVEREST MED Rises 5.72% in Regular Trading, Medical Industry Policy and mRNA Pipeline Progress Boost Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-30 09:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 30, EVEREST MED (01952.HK) rose 5.72% in regular trading, trading at HKD 29.62/share, with turnover of HKD 60.70 million.</p><p>On the news front, ten government departments jointly released the Medical Industry Development Plan, which calls for deepening AI-enabled upgrades across the pharmaceutical value chain, supporting AI and supercomputing applications in target discovery, molecular design, clinical trials, and production management. EVEREST MED, which operates a proprietary mRNA technology platform, plans to initiate an IITIb study of its mRNA tumor vaccine EVM16 in the fourth quarter. The broader biotechnology sector showed strength, with CANSINOBIO surging 17.23%.</p><p>Additionally, the company recently announced the establishment of an ESG committee effective September 28, with four members appointed including Chairman Wu Yifang, further enhancing its corporate governance structure. The company also issued approximately 385,000 shares under its share incentive plan on September 28. Earlier in September, EVEREST MED secured NMPA approval for Xingbituo (etripamil nasal spray) for the treatment of adult PSVT, marking its first approved cardiovascular product in China.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01952","symbol_name":"云顶新耀","start_time":0,"source_url":"","article_id":"1189388761","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189388761","pubTimestamp":1790733173,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 30, EVEREST MED (01952.HK) rose 5.72% in regular trading, trading at HKD 29.62/share, with turnover of HKD 60.70 million.On the news front, ten government departments jointly released...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01952":"云顶新耀"},"translate_title":"动向提醒|珠峰医疗常规交易上涨5.72%，医疗产业政策和mRNA管线进展提振情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":1},"content_text":"On September 30, EVEREST MED (01952.HK) rose 5.72% in regular trading, trading at HKD 29.62/share, with turnover of HKD 60.70 million.On the news front, ten government departments jointly released the Medical Industry Development Plan, which calls for deepening AI-enabled upgrades across the pharmaceutical value chain, supporting AI and supercomputing applications in target discovery, molecular design, clinical trials, and production management. EVEREST MED, which operates a proprietary mRNA technology platform, plans to initiate an IITIb study of its mRNA tumor vaccine EVM16 in the fourth quarter. The broader biotechnology sector showed strength, with CANSINOBIO surging 17.23%.Additionally, the company recently announced the establishment of an ESG committee effective September 28, with four members appointed including Chairman Wu Yifang, further enhancing its corporate governance structure. The company also issued approximately 385,000 shares under its share incentive plan on September 28. Earlier in September, EVEREST MED secured NMPA approval for Xingbituo (etripamil nasal spray) for the treatment of adult PSVT, marking its first approved cardiovascular product in China.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1189388761","isCrawlerRequest":true}